Naphthalene

Naphthalene

SCHEMBL5397697

COC(=O)CCc1ccc(O)c(O)c1.c1ccc2ccccc2c1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.59
IAPP P10997 3/20 0.54
ERCC1 P07992 1/20 0.50
ERCC4 Q92889 1/20 0.50
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
ALOX5 P09917 1/20 0.49
OR51E2 Q9H255 1/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
PTGS1 P23219 1/20 0.49
BLM P54132 1/20 0.49
HIF1A Q16665 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GAA P10253 2/20 0.48
POLB P06746 1/20 0.48
PKM P14618 1/20 0.48
HTT P42858 1/20 0.48
CCR5 P51681 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274537 0.92 APP (0.68) APPIAPPKDM4EALDH1A1MAPT
SCHEMBL5348242 0.86 CYP1A2 (0.57) KDM4EALDH1A1MAPTLMNAPTPN1
SCHEMBL3685390 0.83 CCNC (0.58) APPALDH1A1ALOX5OR51E2PTPN1
SCHEMBL5593842 0.81 CYP1A2 (0.53) KDM4EMAPTLMNAPTPN1
SCHEMBL5371495 0.81 APP (0.49) APPIAPPERCC1ERCC4KDM4E
SCHEMBL5619763 0.80 MEN1 (0.55) APPMAPTALOX5OR51E2HIF1A
SCHEMBL27972225 0.80 APP (0.51) APPIAPPKDM4EALDH1A1MAPT
SCHEMBL18269500 0.80 ALOX5 (0.53) APPIAPPALDH1A1ALOX5OR51E2
SCHEMBL7737580 0.79 PTPN1 (0.60) APPALDH1A1ALOX5OR51E2GAA
SCHEMBL20730239 0.79 APP (0.77) APPIAPPKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7192981-B2 3,4-dihydroxyhydrocinnamic acid derivative BIONUTRIGEN CO., LTD. (KR) 2007-03-20 US claimed
US-20060205813-A1 Naphthalene methyl ester derivatives for treatment of diabetes; insulin receptor signalling BIONUTRIGEN CO., LTD. (KR) 2006-09-14 US claimed
US-7192981-B2 3,4-dihydroxyhydrocinnamic acid derivative BIONUTRIGEN CO., LTD. (KR) 2007-03-20 US disclosed
US-20060205813-A1 Naphthalene methyl ester derivatives for treatment of diabetes; insulin receptor signalling BIONUTRIGEN CO., LTD. (KR) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205813-A1 Naphthalene methyl ester derivatives for treatment of diabetes; insulin receptor signalling GPR119, INSR, INSRR APP 3290/4885IAPP 92/4885ERCC1 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.